Trial watch

References

• Breman JG, Arita I. The confirmation and maintenance of smallpox eradication. N Engl J Med 1980; 303:1263 - 73; http://dx.doi.org/10.1056/NEJM198011273032204; PMID: 6252467
   PubMed Web of Science ®Google Scholar
• Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 2005; 18:21 - 5; PMID: 16200144
   PubMedGoogle Scholar
• Smith KA. Edward jenner and the small pox vaccine. Front Immunol 2011; 2:21; http://dx.doi.org/10.3389/fimmu.2011.00021; PMID: 22566811
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003; 9:269 - 77; http://dx.doi.org/10.1038/nm0303-269; PMID: 12612576
   PubMed Web of Science ®Google Scholar
• Smith KA. Louis pasteur, the father of immunology?. Front Immunol 2012; 3:68; http://dx.doi.org/10.3389/fimmu.2012.00068; PMID: 22566949
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699 - 716; http://dx.doi.org/10.4161/onci.20696; PMID: 22934262
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:894 - 907; http://dx.doi.org/10.4161/onci.20931; PMID: 23162757
   PubMed Web of Science ®Google Scholar
• Oblak A, Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol 2011; 2011:609579; http://dx.doi.org/10.1155/2011/609579; PMID: 22110526
   PubMed Web of Science ®Google Scholar
• Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327:1345 - 50; http://dx.doi.org/10.1126/science.1177319; PMID: 20223979
   PubMed Web of Science ®Google Scholar
• Finn OJ. Tumor immunology at the service of cancer immunotherapy. Curr Opin Immunol 2004; 16:127 - 9; http://dx.doi.org/10.1016/j.coi.2004.02.006; PMID: 15023402
   PubMed Web of Science ®Google Scholar
• Burgio GR. Commentary on the biological self: Toward a “Biological Ego”. From Garrod’s “chemical individuality” to Burnet’s “self”. Thymus 1990; 16:99 - 117; PMID: 2256127
   PubMedGoogle Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12:991 - 1045; http://dx.doi.org/10.1146/annurev.iy.12.040194.005015; PMID: 8011301
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215 - 33; http://dx.doi.org/10.1038/nrd3626; PMID: 22301798
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298 - 306; http://dx.doi.org/10.1038/nrc3245; PMID: 22419253
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012; 13:780 - 8; http://dx.doi.org/10.1038/nrm3479; PMID: 23175281
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643 - 7; http://dx.doi.org/10.1126/science.1840703; PMID: 1840703
   PubMed Web of Science ®Google Scholar
• Parmiani G. Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol Today 1993; 14:536 - 8; http://dx.doi.org/10.1016/0167-5699(93)90183-L; PMID: 8274196
   PubMedGoogle Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25:267 - 96; http://dx.doi.org/10.1146/annurev.immunol.25.022106.141609; PMID: 17134371
   PubMed Web of Science ®Google Scholar
• Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27:83 - 117; http://dx.doi.org/10.1146/annurev.immunol.021908.132544; PMID: 19007331
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265 - 77; http://dx.doi.org/10.1038/nrc3258; PMID: 22437871
   PubMed Web of Science ®Google Scholar
• Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12:237 - 51; http://dx.doi.org/10.1038/nrc3237; PMID: 22437869
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012; 1:1557 - 76; http://dx.doi.org/10.4161/onci.22428; PMID: 23264902
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012; 1:1111 - 34; http://dx.doi.org/10.4161/onci.21494; PMID: 23170259
   PubMed Web of Science ®Google Scholar
• Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries--key challenges and issues. N Engl J Med 2007; 356:1908 - 10; http://dx.doi.org/10.1056/NEJMp078053; PMID: 17494923
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J. Sound efficacy of prophylactic HPV vaccination: Basics and implications. Oncoimmunology 2012; 1:995 - 6; http://dx.doi.org/10.4161/onci.20011; PMID: 23162784
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
   PubMed Web of Science ®Google Scholar
• Yi Y, Noh MJ, Lee KH. Current advances in retroviral gene therapy. Curr Gene Ther 2011; 11:218 - 28; http://dx.doi.org/10.2174/156652311795684740; PMID: 21453283
   PubMed Web of Science ®Google Scholar
• Wasil T, Buchbinder A. Gene therapy in human cancer: report of human clinical trials. Cancer Invest 2000; 18:740 - 6; http://dx.doi.org/10.3109/07357900009012206; PMID: 11107444
   PubMed Web of Science ®Google Scholar
• Sobol RE, Scanlon KJ. Cancer gene therapy clinical trials. Cancer Gene Ther 1995; 2:5 - 6; PMID: 7621255
   PubMed Web of Science ®Google Scholar
• Human gene therapy clinical trials in Europe. Hum Gene Ther 1996; 7:1258 - 9; http://dx.doi.org/10.1089/hum.1996.7.10-1258; PMID: 8793550
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288:669 - 72; http://dx.doi.org/10.1126/science.288.5466.669; PMID: 10784449
   PubMed Web of Science ®Google Scholar
• Bordignon C, Mavilio F, Ferrari G, Servida P, Ugazio AG, Notarangelo LD, et al. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID. Hum Gene Ther 1993; 4:513 - 20; http://dx.doi.org/10.1089/hum.1993.4.4-513; PMID: 8399494
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415 - 9; http://dx.doi.org/10.1126/science.1088547; PMID: 14564000
   PubMed Web of Science ®Google Scholar
• Quetglas JI, John LB, Kershaw MH, Alvarez-Vallina L, Melero I, Darcy PK, et al. Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. Oncoimmunology 2012; 1:1344 - 54; http://dx.doi.org/10.4161/onci.21679; PMID: 23243597
   PubMed Web of Science ®Google Scholar
• Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2:985 - 91; http://dx.doi.org/10.1038/nm0996-985; PMID: 8782455
   PubMed Web of Science ®Google Scholar
• Yoo GH, Hung MC, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M, et al. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 2001; 7:1237 - 45; PMID: 11350889
   PubMed Web of Science ®Google Scholar
• Hui KM, Ang PT, Huang L, Tay SK. Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes. Gene Ther 1997; 4:783 - 90; http://dx.doi.org/10.1038/sj.gt.3300455; PMID: 9338006
   PubMed Web of Science ®Google Scholar
• Rubin J, Galanis E, Pitot HC, Richardson RL, Burch PA, Charboneau JW, et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther 1997; 4:419 - 25; http://dx.doi.org/10.1038/sj.gt.3300396; PMID: 9274718
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Hersh EM, Akporiaye ET, Harris DT, Grogan T, Unger E, et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997; 15:341 - 9; PMID: 8996161
   PubMed Web of Science ®Google Scholar
• Xing X, Zhang S, Chang JY, Tucker SD, Chen H, Huang L, et al. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. Gene Ther 1998; 5:1538 - 44; http://dx.doi.org/10.1038/sj.gt.3300771; PMID: 9930307
   PubMed Web of Science ®Google Scholar
• Maiuri MC, Galluzzi L, Morselli E, Kepp O, Malik SA, Kroemer G. Autophagy regulation by p53. Curr Opin Cell Biol 2010; 22:181 - 5; http://dx.doi.org/10.1016/j.ceb.2009.12.001; PMID: 20044243
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Morselli E, Kepp O, Tajeddine N, Kroemer G. Targeting p53 to mitochondria for cancer therapy. Cell Cycle 2008; 7:1949 - 55; http://dx.doi.org/10.4161/cc.7.13.6222; PMID: 18642442
   PubMed Web of Science ®Google Scholar
• INGN. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs R D 2007; 8:176 - 87; http://dx.doi.org/10.2165/00126839-200708030-00005; PMID: 17472413
   PubMedGoogle Scholar
• Chawla SP, Chua VS, Fernandez L, Quon D, Saralou A, Blackwelder WC, et al. Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma. Mol Ther 2009; 17:1651 - 7; http://dx.doi.org/10.1038/mt.2009.126; PMID: 19532136
   PubMed Web of Science ®Google Scholar
• Madhusudan S, Tamir A, Bates N, Flanagan E, Gore ME, Barton DP, et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res 2004; 10:2986 - 96; http://dx.doi.org/10.1158/1078-0432.CCR-03-0291; PMID: 15131034
   PubMed Web of Science ®Google Scholar
• Xing X, Liu V, Xia W, Stephens LC, Huang L, Lopez-Berestein G, et al. Safety studies of the intraperitoneal injection of E1A--liposome complex in mice. Gene Ther 1997; 4:238 - 43; http://dx.doi.org/10.1038/sj.gt.3300376; PMID: 9135737
   PubMed Web of Science ®Google Scholar
• Smaldone MC, Davies BJ. BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers. Curr Opin Mol Ther 2010; 12:607 - 16; PMID: 20886393
   PubMed Web of Science ®Google Scholar
• Hanna N, Ohana P, Konikoff FM, Leichtmann G, Hubert A, Appelbaum L, et al. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer. Cancer Gene Ther 2012; 19:374 - 81; http://dx.doi.org/10.1038/cgt.2012.10; PMID: 22498722
   PubMed Web of Science ®Google Scholar
• Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000; 1:195 - 203; http://dx.doi.org/10.1006/mthe.2000.0030; PMID: 10933931
   PubMed Web of Science ®Google Scholar
• Singh S, Cunningham C, Buchanan A, Jolly DJ, Nemunaitis J. Toxicity assessment of intratumoral injection of the herpes simplex type I thymidine kinase gene delivered by retrovirus in patients with refractory cancer. Mol Ther 2001; 4:157 - 60; http://dx.doi.org/10.1006/mthe.2001.0430; PMID: 11482988
   PubMed Web of Science ®Google Scholar
• Germano IM, Fable J, Gultekin SH, Silvers A. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol 2003; 65:279 - 89; http://dx.doi.org/10.1023/B:NEON.0000003657.95085.56; PMID: 14682378
   PubMed Web of Science ®Google Scholar
• Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, Garlip G, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 2003; 54:479 - 87; http://dx.doi.org/10.1002/ana.10688; PMID: 14520660
   PubMed Web of Science ®Google Scholar
• Kubo H, Gardner TA, Wada Y, Koeneman KS, Gotoh A, Yang L, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003; 14:227 - 41; http://dx.doi.org/10.1089/10430340360535788; PMID: 12639303
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 2003; 10:737 - 44; http://dx.doi.org/10.1038/sj.cgt.7700634; PMID: 14502226
   PubMed Web of Science ®Google Scholar
• Trudel S, Trachtenberg J, Toi A, Sweet J, Li ZH, Jewett M, et al. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther 2003; 10:755 - 63; http://dx.doi.org/10.1038/sj.cgt.7700626; PMID: 14502228
   PubMed Web of Science ®Google Scholar
• Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C, et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol 1999; 17:3313 - 23; PMID: 10506635
   PubMed Web of Science ®Google Scholar
• Belldegrun A, Tso CL, Zisman A, Naitoh J, Said J, Pantuck AJ, et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 2001; 12:883 - 92; http://dx.doi.org/10.1089/104303401750195854; PMID: 11387054
   PubMed Web of Science ®Google Scholar
• Horton HM, Lalor PA, Rolland AP. IL-2 plasmid electroporation: from preclinical studies to phase I clinical trial. Methods Mol Biol 2008; 423:361 - 72; http://dx.doi.org/10.1007/978-1-59745-194-9_28; PMID: 18370214
   PubMedGoogle Scholar
• Heinzerling L, Burg G, Dummer R, Maier T, Oberholzer PA, Schultz J, et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 2005; 16:35 - 48; http://dx.doi.org/10.1089/hum.2005.16.35; PMID: 15703487
   PubMed Web of Science ®Google Scholar
• Mahvi DM, Henry MB, Albertini MR, Weber S, Meredith K, Schalch H, et al. Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial. Cancer Gene Ther 2007; 14:717 - 23; http://dx.doi.org/10.1038/sj.cgt.7701064; PMID: 17557109
   PubMed Web of Science ®Google Scholar
• Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26:5896 - 903; PMID: 19029422
   PubMed Web of Science ®Google Scholar
• Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD. Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther 2010; 17:360 - 9; http://dx.doi.org/10.1038/gt.2009.159; PMID: 20033066
   PubMed Web of Science ®Google Scholar
• Hernandez-Alcoceba R, Berraondo P. Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin. Oncoimmunology 2012; 1:97 - 9; http://dx.doi.org/10.4161/onci.1.1.17930; PMID: 22720223
   PubMed Web of Science ®Google Scholar
• Khorana AA, Rosenblatt JD, Sahasrabudhe DM, Evans T, Ladrigan M, Marquis D, et al. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther 2003; 10:251 - 9; http://dx.doi.org/10.1038/sj.cgt.7700568; PMID: 12679797
   PubMed Web of Science ®Google Scholar
• Dummer R, Hassel JC, Fellenberg F, Eichmüller S, Maier T, Slos P, et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 2004; 104:1631 - 8; http://dx.doi.org/10.1182/blood-2004-01-0360; PMID: 15161670
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Fong T, Robbins JM, Edelman G, Edwards W, Paulson RS, et al. Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma. Cancer Gene Ther 1999; 6:322 - 30; http://dx.doi.org/10.1038/sj.cgt.7700019; PMID: 10419050
   PubMed Web of Science ®Google Scholar
• Merrick AE, Ilett EJ, Melcher AA. JX-594, a targeted oncolytic poxvirus for the treatment of cancer. Curr Opin Investig Drugs 2009; 10:1372 - 82; PMID: 19943208
   PubMed Web of Science ®Google Scholar
• Malmström PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A, et al. AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial. Clin Cancer Res 2010; 16:3279 - 87; http://dx.doi.org/10.1158/1078-0432.CCR-10-0385; PMID: 20448220
   PubMed Web of Science ®Google Scholar
• Castro JE, Melo-Cardenas J, Urquiza M, Barajas-Gamboa JS, Pakbaz RS, Kipps TJ. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res 2012; 72:2937 - 48; http://dx.doi.org/10.1158/0008-5472.CAN-11-3368; PMID: 22505652
   PubMed Web of Science ®Google Scholar
• Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A 1993; 90:11307 - 11; http://dx.doi.org/10.1073/pnas.90.23.11307; PMID: 8248244
   PubMed Web of Science ®Google Scholar
• Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A 1996; 93:15388 - 93; http://dx.doi.org/10.1073/pnas.93.26.15388; PMID: 8986821
   PubMed Web of Science ®Google Scholar
• Gleich LL, Gluckman JL, Armstrong S, Biddinger PW, Miller MA, Balakrishnan K, et al. Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial. Arch Otolaryngol Head Neck Surg 1998; 124:1097 - 104; PMID: 9776187
   PubMed Web of Science ®Google Scholar
• Rini BI, Selk LM, Vogelzang NJ. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res 1999; 5:2766 - 72; PMID: 10537340
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC, et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001; 7:2285 - 91; PMID: 11489803
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Hutchins L, Nemunaitis J, Atkins M, Schwarzenberger PO. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006; 16:521 - 6; http://dx.doi.org/10.1097/01.cmr.0000232299.44902.41; PMID: 17119453
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Richards J, Kharkevitch D, Atkins MB, Whitman E, Gonzalez R. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 2010; 20:218 - 26; PMID: 20354459
   PubMed Web of Science ®Google Scholar
• Wilson JM. Gendicine: the first commercial gene therapy product. Hum Gene Ther 2005; 16:1014 - 5; http://dx.doi.org/10.1089/hum.2005.16.1014; PMID: 16149899
   PubMed Web of Science ®Google Scholar
• Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16:1016 - 27; http://dx.doi.org/10.1089/hum.2005.16.1016; PMID: 16149900
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Ottensmeier CH, Rice J. DNA vaccines against cancer come of age. Curr Opin Immunol 2010; 22:264 - 70; http://dx.doi.org/10.1016/j.coi.2010.01.019; PMID: 20172703
   PubMed Web of Science ®Google Scholar
• Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011; 239:62 - 84; http://dx.doi.org/10.1111/j.1600-065X.2010.00980.x; PMID: 21198665
   PubMed Web of Science ®Google Scholar
• Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8:108 - 20; http://dx.doi.org/10.1038/nrc2326; PMID: 18219306
   PubMed Web of Science ®Google Scholar
• Shirota H, Petrenko L, Hong C, Klinman DM. Potential of transfected muscle cells to contribute to DNA vaccine immunogenicity. J Immunol 2007; 179:329 - 36; PMID: 17579053
   PubMed Web of Science ®Google Scholar
• Heath WR, Belz GT, Behrens GM, Smith CM, Forehan SP, Parish IA, et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004; 199:9 - 26; http://dx.doi.org/10.1111/j.0105-2896.2004.00142.x; PMID: 15233723
   PubMed Web of Science ®Google Scholar
• Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86 - 9; http://dx.doi.org/10.1038/32183; PMID: 9510252
   PubMed Web of Science ®Google Scholar
• Stoitzner P, Tripp CH, Eberhart A, Price KM, Jung JY, Bursch L, et al. Langerhans cells cross-present antigen derived from skin. Proc Natl Acad Sci U S A 2006; 103:7783 - 8; http://dx.doi.org/10.1073/pnas.0509307103; PMID: 16672373
   PubMed Web of Science ®Google Scholar
• Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010; 2010:174378; http://dx.doi.org/10.1155/2010/174378; PMID: 20368780
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740 - 5; http://dx.doi.org/10.1038/35047123; PMID: 11130078
   PubMed Web of Science ®Google Scholar
• King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998; 4:1281 - 6; http://dx.doi.org/10.1038/3266; PMID: 9809552
   PubMed Web of Science ®Google Scholar
• Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001; 61:3698 - 703; PMID: 11325841
   PubMed Web of Science ®Google Scholar
• Savelyeva N, Munday R, Spellerberg MB, Lomonossoff GP, Stevenson FK. Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nat Biotechnol 2001; 19:760 - 4; http://dx.doi.org/10.1038/90816; PMID: 11479570
   PubMed Web of Science ®Google Scholar
• Wolkers MC, Toebes M, Okabe M, Haanen JB, Schumacher TN. Optimizing the efficacy of epitope-directed DNA vaccination. J Immunol 2002; 168:4998 - 5004; PMID: 11994451
   PubMed Web of Science ®Google Scholar
• Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009; 15:361 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-08-1725; PMID: 19118066
   PubMed Web of Science ®Google Scholar
• Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000; 60:1035 - 42; PMID: 10706121
   PubMed Web of Science ®Google Scholar
• Perales MA, Yuan J, Powel S, Gallardo HF, Rasalan TS, Gonzalez C, et al. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther 2008; 16:2022 - 9; http://dx.doi.org/10.1038/mt.2008.196; PMID: 18797450
   PubMed Web of Science ®Google Scholar
• Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999; 17:253 - 8; http://dx.doi.org/10.1038/6995; PMID: 10096292
   PubMed Web of Science ®Google Scholar
• Boyle JS, Koniaras C, Lew AM. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int Immunol 1997; 9:1897 - 906; http://dx.doi.org/10.1093/intimm/9.12.1897; PMID: 9466317
   PubMed Web of Science ®Google Scholar
• Rice J, King CA, Spellerberg MB, Fairweather N, Stevenson FK. Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines. Vaccine 1999; 17:3030 - 8; http://dx.doi.org/10.1016/S0264-410X(99)00171-1; PMID: 10462238
   PubMed Web of Science ®Google Scholar
• Larocca C, Schlom J. Viral vector-based therapeutic cancer vaccines. Cancer J 2011; 17:359 - 71; http://dx.doi.org/10.1097/PPO.0b013e3182325e63; PMID: 21952287
   PubMed Web of Science ®Google Scholar
• Cawood R, Hills T, Wong SL, Alamoudi AA, Beadle S, Fisher KD, et al. Recombinant viral vaccines for cancer. Trends Mol Med 2012; 18:564 - 74; http://dx.doi.org/10.1016/j.molmed.2012.07.007; PMID: 22917663
   PubMed Web of Science ®Google Scholar
• Zhang T, Sun L, Xin Y, Ma L, Zhang Y, Wang X, et al. A vaccine grade of yeast Saccharomyces cerevisiae expressing mammalian myostatin. BMC Biotechnol 2012; 12:97; http://dx.doi.org/10.1186/1472-6750-12-97; PMID: 23253888
   PubMed Web of Science ®Google Scholar
• Shin SJ, Bae JL, Cho YW, Lee DY, Kim DH, Yang MS, et al. Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA. FEMS Immunol Med Microbiol 2005; 43:155 - 64; http://dx.doi.org/10.1016/j.femsim.2004.07.004; PMID: 15681145
   PubMed Web of Science ®Google Scholar
• Ruitenberg KM, Gilkerson JR, Wellington JE, Love DN, Whalley JM. Equine herpesvirus 1 glycoprotein D expressed in Pichia pastoris is hyperglycosylated and elicits a protective immune response in the mouse model of EHV-1 disease. Virus Res 2001; 79:125 - 35; http://dx.doi.org/10.1016/S0168-1702(01)00337-9; PMID: 11551653
   PubMed Web of Science ®Google Scholar
• Xiang R, Silletti S, Lode HN, Dolman CS, Ruehlmann JM, Niethammer AG, et al. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. Clin Cancer Res 2001; 7:Suppl 856s - 64s; PMID: 11300483
   PubMedGoogle Scholar
• Paglia P, Medina E, Arioli I, Guzman CA, Colombo MP. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 1998; 92:3172 - 6; PMID: 9787153
   PubMed Web of Science ®Google Scholar
• Kiflmariam MG, Yang H, Zhang Z. Gene delivery to dendritic cells by orally administered recombinant Saccharomyces cerevisiae in mice. Vaccine 2012; In press http://dx.doi.org/10.1016/j.vaccine.2012.11.048; PMID: 23200937
   PubMed Web of Science ®Google Scholar
• Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005; 6:769 - 76; http://dx.doi.org/10.1038/ni1223; PMID: 15995707
   PubMed Web of Science ®Google Scholar
• Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA vaccines. Vaccine 2007; 25:3731 - 41; http://dx.doi.org/10.1016/j.vaccine.2007.01.120; PMID: 17350735
   PubMed Web of Science ®Google Scholar
• Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 2006; 40:86 - 97; http://dx.doi.org/10.1016/j.ymeth.2006.05.022; PMID: 16997717
   PubMed Web of Science ®Google Scholar
• Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008; 7:175 - 91; http://dx.doi.org/10.1586/14760584.7.2.175; PMID: 18324888
   PubMed Web of Science ®Google Scholar
• Nardelli-Haefliger D, Romero P, Jichlinski P. What is the influence of vaccination’s routes on the regression of tumors located at mucosal sites?. Oncoimmunology 2012; 1:242 - 3; http://dx.doi.org/10.4161/onci.1.2.18204; PMID: 22720257
   PubMed Web of Science ®Google Scholar
• Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000; 165:2850 - 8; PMID: 10946318
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2012; In press PMID: 23157435
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Rousseau V, Rigoni A, Tesniere A, Delahaye N, et al. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology 2012; 1:271 - 8; http://dx.doi.org/10.4161/onci.18684; PMID: 22737602
   PubMed Web of Science ®Google Scholar
• Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, et al. Activation of dendritic cells by tumor cell death. Oncoimmunology 2012; 1:1218 - 9; http://dx.doi.org/10.4161/onci.20428; PMID: 23170286
   PubMed Web of Science ®Google Scholar
• Pinto A, Rega A, Crother TR, Sorrentino R. Plasmacytoid dendritic cells and their therapeutic activity in cancer. Oncoimmunology 2012; 1:726 - 34; http://dx.doi.org/10.4161/onci.20171; PMID: 22934264
   PubMed Web of Science ®Google Scholar
• Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009; 27:5450 - 9; http://dx.doi.org/10.1016/j.vaccine.2009.07.005; PMID: 19622402
   PubMed Web of Science ®Google Scholar
• Hallermalm K, Johansson S, Bråve A, Ek M, Engström G, Boberg A, et al. Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer. Scand J Immunol 2007; 66:43 - 51; http://dx.doi.org/10.1111/j.1365-3083.2007.01945.x; PMID: 17587345
   PubMed Web of Science ®Google Scholar
• Nguyen-Hoai T, Kobelt D, Hohn O, Vu MD, Schlag PM, Dörken B, et al. HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: Gene gun is superior to jet injector in inducing CTL responses and protective immunity. Oncoimmunology 2012; 1:1537 - 45; http://dx.doi.org/10.4161/onci.22563; PMID: 23264900
   PubMed Web of Science ®Google Scholar
• van den Berg JH, Nujien B, Beijnen JH, Vincent A, van Tinteren H, Kluge J, et al. Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther 2009; 20:181 - 9; http://dx.doi.org/10.1089/hum.2008.073; PMID: 19301471
   PubMed Web of Science ®Google Scholar
• Fest S, Huebener N, Bleeke M, Durmus T, Stermann A, Woehler A, et al. Survivin minigene DNA vaccination is effective against neuroblastoma. Int J Cancer 2009; 125:104 - 14; http://dx.doi.org/10.1002/ijc.24291; PMID: 19291796
   PubMed Web of Science ®Google Scholar
• Niethammer AG, Lubenau H, Mikus G, Knebel P, Hohmann N, Leowardi C, et al. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. BMC Cancer 2012; 12:361; http://dx.doi.org/10.1186/1471-2407-12-361; PMID: 22906006
   PubMed Web of Science ®Google Scholar
• Meng JZ, Dong YJ, Huang H, Li S, Zhong Y, Liu SL, et al. Oral vaccination with attenuated Salmonella enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses. Clin Vaccine Immunol 2010; 17:889 - 94; http://dx.doi.org/10.1128/CVI.00044-10; PMID: 20375244
   PubMed Web of Science ®Google Scholar
• Liu J, Kjeken R, Mathiesen I, Barouch DH. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol 2008; 82:5643 - 9; http://dx.doi.org/10.1128/JVI.02564-07; PMID: 18353952
   PubMed Web of Science ®Google Scholar
• Ahlén G, Söderholm J, Tjelle T, Kjeken R, Frelin L, Höglund U, et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 2007; 179:4741 - 53; PMID: 17878373
   PubMed Web of Science ®Google Scholar
• Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a “prime/boost” strategy for naked DNA vaccination against a tumor antigen. J Immunol 2005; 174:6292 - 8; PMID: 15879128
   PubMed Web of Science ®Google Scholar
• Murakami T, Sunada Y. Plasmid DNA gene therapy by electroporation: principles and recent advances. Curr Gene Ther 2011; 11:447 - 56; http://dx.doi.org/10.2174/156652311798192860; PMID: 22023474
   PubMed Web of Science ®Google Scholar
• Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16:867 - 70; http://dx.doi.org/10.1038/nbt0998-867; PMID: 9743122
   PubMed Web of Science ®Google Scholar
• Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999; 6:508 - 14; http://dx.doi.org/10.1038/sj.gt.3300847; PMID: 10476210
   PubMed Web of Science ®Google Scholar
• Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM, et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci U S A 1999; 96:4262 - 7; http://dx.doi.org/10.1073/pnas.96.8.4262; PMID: 10200250
   PubMed Web of Science ®Google Scholar
• Babiuk S, Baca-Estrada ME, Foldvari M, Storms M, Rabussay D, Widera G, et al. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 2002; 20:3399 - 408; http://dx.doi.org/10.1016/S0264-410X(02)00269-4; PMID: 12213410
   PubMed Web of Science ®Google Scholar
• Tollefsen S, Tjelle T, Schneider J, Harboe M, Wiker H, Hewinson G, et al. Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation. Vaccine 2002; 20:3370 - 8; http://dx.doi.org/10.1016/S0264-410X(02)00289-X; PMID: 12213407
   PubMed Web of Science ®Google Scholar
• Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000; 164:4635 - 40; PMID: 10779767
   PubMed Web of Science ®Google Scholar
• Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, Barnum AB, et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 2004; 11:711 - 21; http://dx.doi.org/10.1038/sj.gt.3302213; PMID: 14724672
   PubMed Web of Science ®Google Scholar
• Qian BJ, Yan F, Li N, Liu QL, Lin YH, Liu CM, et al. MTDH/AEG-1-based DNA vaccine suppresses lung metastasis and enhances chemosensitivity to doxorubicin in breast cancer. Cancer Immunol Immunother 2011; 60:883 - 93; http://dx.doi.org/10.1007/s00262-011-0997-3; PMID: 21400023
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28 - 37; http://dx.doi.org/10.4161/onci.1.1.17938; PMID: 22720209
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1:179 - 88; http://dx.doi.org/10.4161/onci.1.2.19026; PMID: 22720239
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306 - 15; http://dx.doi.org/10.4161/onci.19549; PMID: 22737606
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, et al. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012; 1:493 - 506; http://dx.doi.org/10.4161/onci.20459; PMID: 22754768
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323 - 43; http://dx.doi.org/10.4161/onci.22009; PMID: 23243596
   PubMed Web of Science ®Google Scholar
• Menger L, Vacchelli E, Kepp O, Eggermont A, Tartour E, Zitvogel L, et al. Trial watch: cardiac glycosides and cancer therapy. Oncoimmunology 2013; 2 In press
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, et al. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2; In press http://dx.doi.org/10.4161/onci.22789
   Web of Science ®Google Scholar
• Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1:179 - 88; PMID: 22720239
   PubMed Web of Science ®Google Scholar
• Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001; 75:4040 - 7; http://dx.doi.org/10.1128/JVI.75.9.4040-4047.2001; PMID: 11287553
   PubMed Web of Science ®Google Scholar
• Anderson ED, Mourich DV, Leong JA. Gene expression in rainbow trout (Oncorhynchus mykiss) following intramuscular injection of DNA. Mol Mar Biol Biotechnol 1996; 5:105 - 13; PMID: 8680523
   PubMedGoogle Scholar
• Anderson ED, Mourich DV, Fahrenkrug SC, LaPatra S, Shepherd J, Leong JA. Genetic immunization of rainbow trout (Oncorhynchus mykiss) against infectious hematopoietic necrosis virus. Mol Mar Biol Biotechnol 1996; 5:114 - 22; PMID: 8680524
   PubMedGoogle Scholar
• Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9:1284 - 90; PMID: 12684396
   PubMed Web of Science ®Google Scholar
• Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 2006; 6:8; PMID: 16626110
   PubMedGoogle Scholar
• Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002; 62:5845 - 52; PMID: 12384547
   PubMed Web of Science ®Google Scholar
• Victora GD, Socorro-Silva A, Volsi EC, Abdallah K, Lima FD, Smith RB, et al. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients. Cancer Gene Ther 2009; 16:598 - 608; http://dx.doi.org/10.1038/cgt.2009.9; PMID: 19197326
   PubMed Web of Science ®Google Scholar
• Dangoor A, Lorigan P, Keilholz U, Schadendorf D, Harris A, Ottensmeier C, et al. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother 2010; 59:863 - 73; http://dx.doi.org/10.1007/s00262-009-0811-7; PMID: 20043222
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003; 14:709 - 14; http://dx.doi.org/10.1089/104303403765255110; PMID: 12804135
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 2003; 98:144 - 54; http://dx.doi.org/10.1002/cncr.11462; PMID: 12833467
   PubMed Web of Science ®Google Scholar
• Triozzi PL, Aldrich W, Allen KO, Carlisle RR, LoBuglio AF, Conry RM. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother 2005; 28:382 - 8; http://dx.doi.org/10.1097/01.cji.0000162779.88687.4c; PMID: 16000957
   PubMed Web of Science ®Google Scholar
• Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, et al. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother 2008; 31:215 - 23; http://dx.doi.org/10.1097/CJI.0b013e3181611420; PMID: 18481391
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Yuan J, Houghton AN, Gallardo HF, Rasalan TS, Wang J, et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther 2007; 15:2044 - 50; http://dx.doi.org/10.1038/sj.mt.6300290; PMID: 17726460
   PubMed Web of Science ®Google Scholar
• Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, et al. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun 2009; 9:5; PMID: 19496531
   PubMedGoogle Scholar
• Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 2002; 8:2782 - 7; PMID: 12231517
   PubMed Web of Science ®Google Scholar
• Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004; 91:688 - 94; PMID: 15280930
   PubMed Web of Science ®Google Scholar
• Miller AM, Ozenci V, Kiessling R, Pisa P. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother 2005; 28:389 - 95; http://dx.doi.org/10.1097/01.cji.0000165353.19171.41; PMID: 16000958
   PubMed Web of Science ®Google Scholar
• Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11:781 - 9; http://dx.doi.org/10.1016/S1470-2045(10)70017-6; PMID: 20451455
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678 - 84; http://dx.doi.org/10.1126/science.1224922; PMID: 23019653
   PubMed Web of Science ®Google Scholar
• Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573 - 7; http://dx.doi.org/10.1126/science.1208347; PMID: 22174255
   PubMed Web of Science ®Google Scholar
• Garg AD, Krysko DV, Vandenabeele P, Agostinis P. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother 2012; 61:215 - 21; http://dx.doi.org/10.1007/s00262-011-1184-2; PMID: 22193987
   PubMed Web of Science ®Google Scholar
• Holcmann M, Drobits B, Sibilia M. How imiquimod licenses plasmacytoid dendritic cells to kill tumors. Oncoimmunology 2012; 1:1661 - 3; http://dx.doi.org/10.4161/onci.22033; PMID: 23264929
   PubMed Web of Science ®Google Scholar
• Gerritsen WR. The evolving role of immunotherapy in prostate cancer. Ann Oncol 2012; 23:Suppl 8 viii22-7; http://dx.doi.org/10.1093/annonc/mds259; PMID: 22918924
   PubMedGoogle Scholar
• Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006; 236:229 - 38; http://dx.doi.org/10.1016/j.canlet.2005.05.021; PMID: 16046056
   PubMed Web of Science ®Google Scholar
• Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996; 56:860 - 5; PMID: 8631025
   PubMed Web of Science ®Google Scholar
• Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9:67 - 81; http://dx.doi.org/10.1006/scbi.1998.0119; PMID: 10202129
   PubMed Web of Science ®Google Scholar
• Tiernan JP, Perry SL, Verghese ET, West NP, Yeluri S, Jayne DG, et al. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br J Cancer 2013; In press http://dx.doi.org/10.1038/bjc.2012.605; PMID: 23322207
   PubMed Web of Science ®Google Scholar
• Zhao L, Mou DC, Leng XS, Peng JR, Wang WX, Huang L, et al. Expression of cancer-testis antigens in hepatocellular carcinoma. World J Gastroenterol 2004; 10:2034 - 8; PMID: 15237429
   PubMed Web of Science ®Google Scholar
• Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer 2009; 9:675 - 81; http://dx.doi.org/10.1038/nrc2717; PMID: 19701243
   PubMed Web of Science ®Google Scholar
• Prins RM, Odesa SK, Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 2003; 63:8487 - 91; PMID: 14679014
   PubMed Web of Science ®Google Scholar
• Sarantou T, Chi DD, Garrison DA, Conrad AJ, Schmid P, Morton DL, et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 1997; 57:1371 - 6; PMID: 9102226
   PubMed Web of Science ®Google Scholar
• Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008; 14:1065 - 72; http://dx.doi.org/10.1158/1078-0432.CCR-07-1569; PMID: 18258665
   PubMed Web of Science ®Google Scholar
• Kanety H, Kattan M, Goldberg I, Kopolovic J, Ravia J, Menczer J, et al. Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br J Cancer 1996; 73:1069 - 73; http://dx.doi.org/10.1038/bjc.1996.206; PMID: 8624265
   PubMed Web of Science ®Google Scholar
• Lundberg K, Roos AK, Pavlenko M, Leder C, Wehrum D, Guevara-Patiño J, et al. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols. Vaccine 2009; 27:1557 - 65; http://dx.doi.org/10.1016/j.vaccine.2009.01.011; PMID: 19171173
   PubMed Web of Science ®Google Scholar
• Mubiru JN, Hubbard GB, Dick EJ Jr., Furman J, Troyer DA, Rogers J. Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases. Prostate 2008; 68:1546 - 54; http://dx.doi.org/10.1002/pros.20814; PMID: 18668524
   PubMed Web of Science ®Google Scholar
• Dale W. Prostate cancer: PSA testing in older men--are we following the guidelines?. Nat Rev Urol 2012; 9:357 - 8; http://dx.doi.org/10.1038/nrurol.2012.115; PMID: 22641163
   PubMed Web of Science ®Google Scholar
• Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 2010; 16:3548 - 61; http://dx.doi.org/10.1158/1078-0432.CCR-09-2797; PMID: 20606037
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, Vallieres E, et al. Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther 2006; 13:1185 - 91; http://dx.doi.org/10.1016/j.ymthe.2006.01.013; PMID: 16581300
   PubMed Web of Science ®Google Scholar
• Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, Gilbert SC, et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 2005; 113:259 - 66; http://dx.doi.org/10.1002/ijc.20569; PMID: 15386406
   PubMed Web of Science ®Google Scholar
• Todorova K, Ignatova I, Tchakarov S, Altankova I, Zoubak S, Kyurkchiev S, et al. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded. Cancer Immun 2005; 5:1; PMID: 15641767
   PubMedGoogle Scholar
• Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol 2000; 38:208 - 17; http://dx.doi.org/10.1159/000020281; PMID: 10895014
   PubMed Web of Science ®Google Scholar
• Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 2002; 8:1028 - 37; PMID: 12006515
   PubMed Web of Science ®Google Scholar
• Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004; 103:317 - 26; http://dx.doi.org/10.1097/01.AOG.0000110246.93627.17; PMID: 14754702
   PubMed Web of Science ®Google Scholar
• Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005; 11:4430 - 6; http://dx.doi.org/10.1158/1078-0432.CCR-04-2111; PMID: 15958627
   PubMed Web of Science ®Google Scholar
• Guirnalda PD, Paterson Y. Vaccination with immunotherapeutic Listeria monocytogenes induces IL-17(+) γδ T cells in a murine model for HPV associated cancer. Oncoimmunology 2012; 1:822 - 8; http://dx.doi.org/10.4161/onci.20491; PMID: 23162749
   PubMed Web of Science ®Google Scholar
• Du JW, Xu KY, Fang LY, Qi XL. Clinical significance of Mena and Her-2 expression in breast cancer. Eur J Gynaecol Oncol 2012; 33:455 - 8; PMID: 23185786
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, et al, Inflammatory Breast Cancer Research Group. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 2008; 112:1905 - 11; http://dx.doi.org/10.1002/cncr.23350; PMID: 18300243
   PubMed Web of Science ®Google Scholar
• Foy KC, Miller MJ, Moldovan N, Bozanovic T, Carson Iii WE, Kaumaya PT. Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer. Oncoimmunology 2012; 1:1004 - 16; http://dx.doi.org/10.4161/onci.21057; PMID: 23170249
   PubMed Web of Science ®Google Scholar
• Foy KC, Miller MJ, Moldovan N, Carson Iii WE, Kaumaya PT. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. Oncoimmunology 2012; 1:1048 - 60; http://dx.doi.org/10.4161/onci.20708; PMID: 23170253
   PubMed Web of Science ®Google Scholar
• Chu EA, Wu JM, Tunkel DE, Ishman SL. Nasopharyngeal carcinoma: the role of the Epstein-Barr virus. Medscape J Med 2008; 10:165; PMID: 18769688
   PubMedGoogle Scholar
• Smith C, Khanna R. A new approach for cellular immunotherapy of nasopharyngeal carcinoma. Oncoimmunology 2012; 1:1440 - 2; http://dx.doi.org/10.4161/onci.21286; PMID: 23243622
   PubMed Web of Science ®Google Scholar
• Li H, Lakshmikanth T, Carbone E, Selivanova G. A novel facet of tumor suppression by p53: Induction of tumor immunogenicity. Oncoimmunology 2012; 1:541 - 3; http://dx.doi.org/10.4161/onci.19409; PMID: 22754780
   PubMed Web of Science ®Google Scholar
• Vojtĕsek B, Lane DP. Regulation of p53 protein expression in human breast cancer cell lines. J Cell Sci 1993; 105:607 - 12; PMID: 8408290
   PubMed Web of Science ®Google Scholar
• Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992; 52:4196 - 9; PMID: 1638534
   PubMed Web of Science ®Google Scholar
• Bodner SM, Minna JD, Jensen SM, D’Amico D, Carbone D, Mitsudomi T, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992; 7:743 - 9; PMID: 1565469
   PubMed Web of Science ®Google Scholar
• Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene 2007; 26:2145 - 56; http://dx.doi.org/10.1038/sj.onc.1210280; PMID: 17401423
   PubMed Web of Science ®Google Scholar
• Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 2005; 331:834 - 42; http://dx.doi.org/10.1016/j.bbrc.2005.03.190; PMID: 15865939
   PubMed Web of Science ®Google Scholar
• Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9:874 - 85; http://dx.doi.org/10.1038/nrc2761; PMID: 19935676
   PubMed Web of Science ®Google Scholar
• Limacher JM, Quoix E. TG4010: A therapeutic vaccine against MUC1 expressing tumors. Oncoimmunology 2012; 1:791 - 2; http://dx.doi.org/10.4161/onci.19863; PMID: 22934285
   PubMed Web of Science ®Google Scholar
• Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol 2012; 39:296 - 304; http://dx.doi.org/10.1053/j.seminoncol.2012.02.010; PMID: 22595052
   PubMed Web of Science ®Google Scholar
• Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999; 59:5800 - 7; PMID: 10582702
   PubMed Web of Science ®Google Scholar
• Zhao D, Chen P, Yang H, Wu Y, Zeng X, Zhao Y, et al. Live attenuated measles virus vaccine induces apoptosis and promotes tumor regression in lung cancer. Oncol Rep 2013; 29:199 - 204; PMID: 23129111
   PubMed Web of Science ®Google Scholar
• Sion-Vardy N, Lasarov I, Delgado B, Gopas J, Benharroch D, Ariad S. Measles virus: evidence for association with lung cancer. Exp Lung Res 2009; 35:701 - 12; http://dx.doi.org/10.3109/01902140902853176; PMID: 19895323
   PubMed Web of Science ®Google Scholar
• Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999; 5:774 - 9; http://dx.doi.org/10.1038/10495; PMID: 10395322
   PubMed Web of Science ®Google Scholar
• Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393:478 - 80; http://dx.doi.org/10.1038/30996; PMID: 9624004
   PubMed Web of Science ®Google Scholar